Bioresorbable Vascular Scaffold Use in a Case of In-stent Restenosis

Cadrin‐Tourigny, Julia; Liang, Dong; Maehara, Akiko; Schampaert, Erick; Généreux, Philippe

doi:10.5935/abc.20140098

Cited by 4 publications

(3 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A previous in vivo study in bioresorbable Mg-based alloys has reported on their high compatibility with body tissue and intrinsic dissolution in body fluids 40 . Early clinical studies of a balloon-expandable Mg alloy bioresorbable stent by Biotronik, poly-L-lactic acid (PLLA) self-expanding stent by Kyoto Medical Planning, as well as bioresorbable vascular scaffold (BVS) by Abbott have been reported 10 , 41 , 42 . In particular, the Mg stent was presented as well-expanded on deployment without immediate recoil or high restenosis rate with an in-stent late loss 43 .…”

Section: Discussionmentioning

confidence: 99%

Expandable Mg-based Helical Stent Assessment using Static, Dynamic, and Porcine Ex Vivo Models

Koo

Tiasha

Shanov

et al. 2017

Sci Rep

View full text Add to dashboard Cite

A bioresorbable metallic helical stent was explored as a new device opportunity (magnesium scaffold), which can be absorbed by the body without leaving a trace and simultaneously allowing restoration of vasoreactivity with the potential for vessel remodeling. In this study, developed Mg-based helical stent was inserted and expanded in vessels with subsequent degradation in various environments including static, dynamic, and porcine ex vivo models. By assessing stent degradation in three different environments, we observed: (1) stress- and flow-induced degradation; (2) a high degradation rate in the dynamic reactor; (3) production of intermediate products (MgO/Mg(OH)2 and Ca/P) during degradation; and (4) intermediate micro-gas pocket formation in the neighboring tissue ex vivo model. Overall, the expandable Mg-based helical stent employed as a scaffold performed well, with expansion rate (>100%) in porcine ex vivo model.

show abstract

Section: Discussionmentioning

confidence: 99%

Expandable Mg-based Helical Stent Assessment using Static, Dynamic, and Porcine Ex Vivo Models

Koo

Tiasha

Shanov

et al. 2017

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Mechanisms of ST differ depending on the time frame after PCI, with early events mostly attributable to procedural issues (such as dissection, incomplete stent apposition, or incomplete stent expansion) and late events more likely linked to stent factors, antiplatelet cessation therapy, and vascular response. 14 All the aforementioned studies highlight the importance of meticulous lesion preparation and postimplantation intravascular imaging aimed at ameliorating the risk of early ST (secondary to suboptimal implantation) and optimize outcomes. In line with the preceding goals, Mattesini et al 15 reported that systematic aggressive lesion preparation, highpressure dilation after the procedure, and the use of OCT for optimization can attain acute BVS mechanical performance comparable to that of current DES platforms.…”

Section: Discussionmentioning

confidence: 99%

Procedural Feasibility and Clinical Outcomes in Propensity-Matched Patients Treated With Bioresorbable Scaffolds vs New-Generation Drug-Eluting Stents

Sato

Latib

Panoulas

et al. 2015

Canadian Journal of Cardiology

View full text Add to dashboard Cite

“…Wymaga to potwierdzenia w większych próbach klinicznych. Obecnie stosowanie BVS w tej sytuacji klinicznej należy traktować jako off-label [58][59][60][61].…”

Section: Restenoza W Stencieunclassified

Bioresorbable scaffolds in the treatment of coronary artery disease. Expert consensus statement of the Association of Cardiovascular Interventions of the Polish Cardiac Society (ACVI PCS)

Reczuch¹,

Milewski

Wąsek

et al. 2017

Kardiol Pol

View full text Add to dashboard Cite

Bioresorbable scaffold coated with antimitotic drug is the latest development in the coronary stents technology. The concept of temporary scaffolding and natural vessel healing after angioplasty is a very attractive alternative to conventional metal stents. The results of the first observational studies have confirmed their ultimate biodegradation. Newest results of randomised trials and registries in broader clinical and anatomical indications also revealed the limitations of the first generation of scaffolds. The relatively thick polymeric struts and compliance with specific implantation protocol may influence the results. In this document, the group of experts presents the current state of knowledge, with a particular focus on the advantages and limitations of the new technology; it presents practical guidelines for optimal implantation techniques and clarifies documented indications for patients and lesions selection.

show abstract

Bioresorbable Vascular Scaffold Use in a Case of In-stent Restenosis

Cited by 4 publications

References 5 publications

Expandable Mg-based Helical Stent Assessment using Static, Dynamic, and Porcine Ex Vivo Models

Expandable Mg-based Helical Stent Assessment using Static, Dynamic, and Porcine Ex Vivo Models

Procedural Feasibility and Clinical Outcomes in Propensity-Matched Patients Treated With Bioresorbable Scaffolds vs New-Generation Drug-Eluting Stents

Bioresorbable scaffolds in the treatment of coronary artery disease. Expert consensus statement of the Association of Cardiovascular Interventions of the Polish Cardiac Society (ACVI PCS)

Contact Info

Product

Resources

About